MaxLinear heads into the first week of June having shed 7.7% over the past five sessions, a notable pullback after a violent post-earnings re-rating that took the stock from the low $40s to nearly $110 in a matter of weeks.
The most material change since last week's note is in short positioning — and it tells a story of rapid capitulation. Short interest has collapsed by nearly 45% over the past month, from roughly 5.3 million shares to under 3 million, bringing the SI as a percentage of free float down to just 3.4%. In a single week alone, shorts covered 25% of their position. That wave of covering has largely run its course: the lending market is as loose as it has been all year, with availability running at nearly 5,000% of short interest — meaning shares to borrow are extraordinarily plentiful and borrow cost has settled back to just 0.42% annually after briefly spiking to nearly 8% in late April. There is no squeeze pressure here. The squeeze already happened, and what remains is a residual 3.4% short base operating in a frictionless borrow environment.
Options positioning has become less cautious than the prior period, but has edged back from its most bullish extreme. The put/call ratio is 0.37, slightly below its 20-day average of 0.44, and a fraction of a standard deviation below that mean — not a meaningful signal either way. What is notable is the directional arc: the PCR ran above 0.9 through late April during peak uncertainty, then collapsed toward 0.27 in mid-May as confidence surged, and has now drifted back to just above 0.37 as the stock digested its gains. Options traders are no longer aggressively bullish, but they are not hedging heavily either.
The Street angle remains the central tension the previous note identified — and it has not resolved. The mean analyst price target stands around $63, well below the current price of $88.76. Benchmark's $125 target, initiated May 27, is the only published figure that acknowledges where shares actually trade. The post-earnings upgrades from Loop Capital, Needham, and Stifel in late April all carry targets of $49–$75 — numbers the stock has already traded through. EPS momentum over 90 days ranks in the 92nd percentile, and the analyst recommendation divergence score sits in the 91st percentile, confirming the Street remains unusually split on fair value. The bull case centres on infrastructure revenue surging 136% in Q1 2026, the Panther product cycle, and deepening partnerships with Samsung and TSMC. The bear case flags revenue concentration and the uncertain trajectory of the Annapurna platform due in 2028. The stock's P/E now runs near 57x on a trailing basis, with EV/EBITDA at 41x — multiples that demand continued execution.
Insider activity since the April earnings print is worth flagging. CEO and founder Kishore Seendripu sold 33,682 shares on May 20 at $96.77, realising roughly $3.3 million. Director Thomas Pardun sold 11,000 shares at $105 on May 26. The Principal Accounting Officer also sold in both May 8 and May 25 transactions. The 90-day net insider position is technically positive in share count terms due to award grants, but the cash-market picture is entirely one-directional: insiders have been sellers throughout the stock's advance. That is not unusual following a move of this magnitude, but the volume and breadth of selling at prices between $77 and $105 is a relevant backdrop to the pullback toward $89 this week.
The next scheduled earnings event is July 22. Between now and then, what matters most is whether the analyst community closes the gap between published targets and market price — and whether Panther-driven revenue concentration begins to broaden toward the hyperscale and infrastructure customers that underpin the bull case.
See the live data behind this article on ORTEX.
Open MXL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
